Table 1.
Descriptive statistics of the cohort
| Variables | Total (N = 310)1 | Chemotherapy (N = 223) | No Chemotherapy (n = 87) | P value2 |
|---|---|---|---|---|
| Age | 58.3 (9.7) | 57.0 (8.7) | 61.4 (11.3) | 0.002 |
| Sex | ||||
| Male | 167 (53.9%) | 117 (52.5%) | 50 (57.5%) | 0.4 |
| Female | 143 (46.9%) | 106 (47.5%) | 37 (42.35%) | |
| Race | ||||
| White | 271 (87.4%) | 197 (88.3%) | 74 (85.1%) | 0.2 |
| Black | 29 (9.4%) | 21 (9.4%) | 8 (9.2%) | |
| Other | 10 (3.2%) | 5 (2.2%) | 5 (5.7%) | |
| Primary payer | ||||
| Private Insurance | 154 (49.7%) | 116 (52.0%) | 38 (43.7%) | 0.01 |
| Government Insurance | 132 (42.6%) | 85 (38.1%) | 47 (54.0%) | |
| No Insurance or Unknown | 24 (7.7%) | 22 (9.9%) | 2 (2.3%) | |
| Median Income Quartiles | ||||
| <$38,000 | 57 (18.6%) | 36 (16.4%) | 21 (24.1%) | 0.4 |
| $38,000-$47,999 | 79 (25.7%) | 58 (26.4%) | 21 (24.1%) | |
| $48,000-$62,999 | 86 (28.0%) | 65 (29.5%) | 21 (24.1%) | |
| $63,000 + | 85 (27.7%) | 61 (27.7%) | 24 (27.6%) | |
| % No High School Degree | ||||
| >=21% | 58 (18.9%) | 37 (16.8%) | 21 (24.1%) | 0.4 |
| 13-20% | 75 (24.4%) | 53 (24.1%) | 22 (25.3%) | |
| 7.0-12.9% | 103 (33.6%) | 77 (35.0%) | 26 (29.9%) | |
| <7% | 71 (23.1%) | 53 (24.1%) | 18 (20.7%) | |
| Residence | ||||
| Metro | 243 (78.4%) | 180 (80.7%) | 63 (72.4%) | 0.1 |
| Urban | 49 (15.8%) | 30 (13.5%) | 19 (21.8%) | |
| Rural | 6 (1.9%) | 3 (1.3%) | 3 (3.4%) | |
| Unknown | 12 (3.9%) | 10 (4.5%) | 2 (2.3%) | |
| Facility Type | ||||
| Community Cancer Program | 24 (8.0%) | 17 (7.9%) | 7 (8.2%) | 0.8 |
| Comprehensive Community Cancer Program | 107 (35.5%) | 79 (36.6%) | 28 (32.9%) | |
| Academic/Research Program | 133 (44.2%) | 92 (42.6%) | 41 (48.2%) | |
| Integrated Network Cancer Program | 37 (12.3%) | 28 (13.0%) | 9 (10.6%) | |
| Site | ||||
| Main bronchus | 2 (0.6%) | 2 (0.9%) | 0.7 | |
| Upper lobe | 206 (66.5%) | 147 (65.9%) | 59 (67.8%) | |
| Middle lobe | 11 (3.5%) | 7 (3.1%) | 4 (4.6%) | |
| Lower lobe | 75 (24.2%) | 54 (24.2%) | 21 (24.1%) | |
| Overlapping lesion of lung | 9 (2.9%) | 8 (3.6%) | 1 (1.1%) | |
| Lung, NOS | 7 (2.3%) | 5 (2.2%) | 2 (2.3%) | |
| Histology | ||||
| Squamous | 36 (11.6%) | 26 (11.7%) | 10 (11.5%) | 0.9 |
| Adenocarcinoma | 213 (68.7%) | 152 (68.2%) | 61 (70.1%) | |
| Others | 61 (19.7%) | 45 (20.2%) | 16 (18.4%) | |
| Pathologic N Stage | ||||
| N0 | 231 (74.5%) | 164 (73.5%) | 67 (77.0%) | 0.5 |
| N1 | 79 (25.5%) | 59 (26.5%) | 20 (23.0%) | |
| Pathologic T stage | ||||
| T0 | 2 (0.6%) | 2 (0.9%) | 0.1 | |
| T1 | 72 (23.3%) | 44 (19.8%) | 28 (32.2%) | |
| T2 | 159 (51.5%) | 115 (51.8%) | 44 (50.6%) | |
| T3 | 64 (20.7%) | 52 (23.4%) | 12 (13.8%) | |
| T4 | 12 (3.9%) | 9 (4.1%) | 3 (3.4%) | |
| Grade | ||||
| I/II | 81 (26.1%) | 56 (25.1%) | 25 (28.7%) | 0.5 |
| III/IV | 183 (59.0%) | 131 (58.7%) | 52 (59.8%) | |
| Unknown | 46 (14.8%) | 36 (16.1%) | 10 (11.5%) | |
| Surgery | ||||
| Lobectomy | 294 (94.8%) | 210 (94.2%) | 84 (96.6%) | 0.3 |
| Pneumonectomy | 16 (5.2%) | 13 (5.8%) | 3 (3.4%) | |
| Surgical Approach | ||||
| VATS | 67 (21.6%) | 45 (20.2%) | 22 (25.3%) | 0.6 |
| Thoracotomy | 174 (56.1%) | 128 (57.4%) | 46 (52.9%) | |
| Unknown | 69 (22.3%) | 50 (22.4%) | 19 (21.8%) | |
| Charlson Deyo Score | ||||
| 0 | 209 (67.4%) | 150 (67.3%) | 59 (67.8%) | 0.9 |
| 1 or 2 | 101 (32.6%) | 73 (32.7%) | 28 (32.2%) | |
| Radiation | ||||
| Yes | 261 (86.7%) | 199 (93.0%) | 62 (71.3%) | < 0.001 |
| No | 49 (13.3%) | 4 (7%) | 25 (28.7%) | |
Sociodemographic, and clinicopathological variables were compared across the two treatment groups using Pearson’s Chi-square test and Wilcoxon rank sum test for categorical and continuous variables, respectively. All significantly different variable (p < 0.05) p values are highlighted in bold.
NOS, Not otherwise specified; VATS, video-assisted thoracoscopic surgery
1
mean (SD); n (%)
2
Pearson's Chi-square test; Wilcoxon rank sum test